A highly-parallelized and low-sample-size chip for simultaneous detection of protein and nucleic acid biomarkers in hepatocellular carcinoma

Simultaneous analyzing multiple protein and nucleic acid biomarkers in one clinical sample can provide clinically valuable results for the diagnosis, monitoring, and management of diseases. However, current diagnostic platforms primarily rely on independent detection of proteins/nucleic acids, which is time-consuming and laborintensive. Here, we develop a Highly-Parallelized and Low-Sample-Size (HPLSS) chip for simultaneously detecting protein and nucleic acid biomarker in hepatocellular carcinoma (HCC). We assess the limit of detections for five different markers (0.14 ng mL(-1) for alpha fetoprotein (AFP), 0.09 ng mL(-1) for protein induced by vitamin K absence or antagonist-II (PIVKA II), 7.94 copies mu L-1 for microRNA-21, 4.88 copies mu L-1 for microRNA122, and 5.83 copies mu L-1 for microRNA-223). We also evaluate the performance using clinical samples and compared it with commercial kits. Our method exhibited a small sample volume required (similar to 20 mu L), multiplexed ability and adjustable throughput (five targets in each of six samples in one assay). Importantly, the combined evaluation of multiple biomarkers of different dimensions can improve the specificity and sensitivity of diagnosis. This study has achieved the multidimensional detection of tumor biomarkers, which has great potential for early and accurate cancer diagnosis.